Mary Ann Martin
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1750305470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,440 and has fallen 72.8% since, to $664 in 2022.
Across 365 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$932
- Sanofi-aventis U.S. LLC$556
- Abbott$526
- Insulet Corporation$382
- Tandem Diabetes Care, Inc.$300
- plus $3K from 30 others
Across 4 payments — averaging $2394.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$10K
What the payments were for
- Speaking & faculty fees$4056%
- Food & beverage$6,29494%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 51 | $1,049 |
| Novo Nordisk | 44 | $932 |
| Sanofi-aventis U.S. LLC | 20 | $556 |
| Abbott | 23 | $526 |
| Insulet Corporation | 10 | $382 |
| Tandem Diabetes Care, Inc. | 1 | $300 |
| Dexcom, Inc. | 54 | $290 |
| Amgen(2 entities) | 12 | $266 |
| Lifescan, Inc. | 10 | $246 |
| AbbVie | 11 | $194 |
| Mannkind Corporation | 38 | $172 |
| Ultragenyx Pharmaceutical Inc. | 9 | $171 |
| Merck | 9 | $169 |
| Lilly USA, LLC | 7 | $158 |
| Medtronic(2 entities) | 8 | $157 |
| Corcept Therapeutics | 8 | $148 |
| IBSA Pharma Inc. | 5 | $108 |
| Sanofi | 1 | $105 |
| BD | 4 | $84 |
| Boehringer Ingelheim | 5 | $83 |
| Arbor Pharmaceuticals, Inc. | 4 | $78 |
| Shire North American Group Inc | 4 | $76 |
| Clarus Therapeutics Inc. | 4 | $67 |
| Antares Pharma, Inc. | 2 | $45 |
| Johnson & Johnson | 3 | $41 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| Companion Medical, Inc. | 2 | $26 |
| Radius Health, Inc. | 2 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| GRT US Holding, Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$300
- TOUJEO$245
- Omnipod$186
- Ozempic$125
- SOLIQUA 100/33$105
How this compares
$6,705 in reported general payments places this provider in the 60th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.